Form 4: Director Mathers' Trust Receives RYTM Shares

Rhythm Pharmaceuticals Director Edward T. Mathers' revocable trust received 4,199 shares of common stock through a pro rata distribution from NEA Partners 13, L.P. for no consideration.

Summary

• Director Edward T. Mathers' revocable trust, the Mathers Trust, received 4,199 shares of Rhythm Pharmaceuticals, Inc. common stock.
• The shares were distributed pro rata by NEA Partners 13, L.P. to its limited partners for no consideration.
• The transaction occurred on March 12, 2026.
• Following this transaction, the Mathers Trust indirectly holds 14,168 shares, and Edward T. Mathers directly holds 7,000 shares.
• Edward T. Mathers disclaims beneficial ownership of any portion of the Mathers Trust's holdings in which he has no pecuniary interest.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it represents an increase in a director's indirect beneficial ownership, albeit through a non-cash distribution, indicating continued long-term holding.

Positives

• Increased indirect beneficial ownership for Director Mathers' trust without direct cost.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that insider transactions, even those involving distributions for no consideration, provide insight into the ownership structure and potential long-term commitment of key personnel. While not a direct purchase, the increased indirect holding by a director's trust can be viewed as a stable, long-term stake.

Comparison to Industry Standards

• This is a routine insider ownership disclosure. There are no specific comparable companies or projects for this type of transaction, as it reflects an internal fund distribution rather than a market-driven investment decision.

Related Party Transactions

• NEA Partners 13, L.P. distributed shares to the Mathers Trust, where Edward T. Mathers (a director of Rhythm Pharmaceuticals) is the trustee. This constitutes a related party transaction as it involves an entity (NEA Partners 13) and a trust associated with a company director.

Stakeholder Impact

• Shareholders: No direct impact on the company's outstanding shares or market capitalization, as this is a transfer of existing shares. It clarifies the beneficial ownership structure of a director.

Key Dates

Recommendation

This Form 4 filing reports a routine insider transaction involving a pro rata distribution of shares to a director's trust for no consideration. It does not reflect a direct purchase or sale decision by the insider based on new information, nor does it alter the company's fundamentals. Therefore, it provides no new information to warrant a change in investment recommendation, suggesting a 'hold' position for existing investors.

Keywords

Rhythm Pharmaceuticals, RYTM, Edward T Mathers, Form 4, Insider Transaction, Beneficial Ownership, Stock Distribution, NEA Partners 13, Director